Baird analyst Michael Ulz reiterated an Outperform rating and $3 price target on Genocea Biosciences (NASDAQ: GNCA) calling news this ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE